IMU - Imugene Limited

[yogi-in-oz]

Hi folks,

IMU ..... expecting this one to jump out
of the gate strongly, in 2006.

Key dates for IMU in January may be:

04012006 ..... significant and positive

09-11012006 ..... significant pullback ???

12-13012006 ..... minor and positive news here???

23012006 ..... minor and negative,intraday only?

31012006 ..... significant and negative news???

happy new year

yogi

 

[tarnor]

Re: IMU alert ..... astrostuff .....

It did have a little rise the other day... this one is traditionally leaky before announcements..
If someone knew this history they could easily come up with a january 4th announcement guesstimate..

Still at least ya picked a bio and not a oiler this time..

seems like sham spam to me , happy to be proven wrong bring on feb

 

[yogi-in-oz]

Hi folks,

IMU ..... chart starting to look interesting
again, as it tests support ..... would like
to see a bounce off 13 cents, in early
March 2006 (???)

Over the next couple of months, we will be
alert for IMU news, around:

03-06032006 ..... spotlight on IMU ??? ...

15-16032006 ..... changes in management???

24-27032006 ..... positive news ???

03042006 ..... minor cycle

19042006 ..... 2 cycles here ... finance-related???
..... significant and positive???
..... new technology ???

26042006 ..... minor news???

04052006 ..... negative spotlight on IMU???

08052006 ..... significant and positive???

12052006 ..... VERY significant and negative news???


happy days

yogi



=====

 

[Karren]

I'm new to the forum ... so Hi everyone!

Imugene has just passed over the horizontal downtrend (recent and longterm) with good news and volume so thought it might be time to start a thread.

Imugene is a biotech company and it's poultry and pig portfolio is targeting a worldwide US$3 billion annual market with five lead vaccine products under development.
www.imugene.com


LATEST COMPANY RELEASE

$880,000 Grant ... 8 November 2006: Imugene (ASX:IMU) has been offered an Australian government Commercial Ready Grant to produce and test vaccines to protect chickens from the H5N1 avian influenza virus.
Imugene has already announced the construction of vaccine candidates and that these will undergo live testing in a high security facility operated by Benchmark Biolabs in Nebraska, US. These trials begin later this month and are scheduled for completion in January 2007.
Imugene has designed vaccines to be inexpensive, safe, and easy to mass administer in poultry sheds. This will enable rapid and widespread protection of commercial poultry without the need to individually inject each bird.
The vaccines for egg-laying and meat producing chickens could make a substantial contribution to protecting poultry from avian influenza.
The Imugene vaccines use technology that enables identification of naturally infected and vaccinated birds. This is very important for the international poultry trade and for eradication programs.
Industry Minister Ian Macfarlane congratulated Imugene Limited on being offered the grant. "Bird flu is deadly and unpredictable and a project to test vaccines to protect chickens from the virus will be an enormous breakthrough," Mr Macfarlane said.
"The Australian Government is committed to helping companies such as Imugene develop vaccines which can be used globally and rid the world of a deadly threat. What is very encouraging is that the company is already primed to commence trials soon, with a completion date in early in 2007.”
“This funding is important for Imugene and its shareholders as it strengthens our financial resources for product development,” said Dr Warwick Lamb, managing director of Imugene.

I've only started trading this year (but studying hard and luving it!)
so I was hoping someone might know why this share fell from $35???! or the best way to find out.

I've really been enjoying the forum ... especially some of the great posts from the advanced traders ... thank you!

Cheers,
Karren

 

[toc_bat]

yogi

i am intrigues, how can you put such long term forecasts on items like the release of positive news. Are you working for the company? To ba able to state that news will be released in 6 months time or more?

I ahve to admit that I do not really understand your posts.

bye

 

[Biggle]

News today from the ASX of Imugene birdflu vaccine trials being successful in the US could not have come at a better time, considering a third outbreak of birdflu has just been confirmed in Japan. I believe an accellerated program to complete tests and hopefully release a successful product to market may be on the cards. IMHO.

 

[motion]

what a cracker of a morning up 36% at open.... with news of Avian Influenza Poultry Vaccine trial....

 

[Sprinter79]

Down a bit today, profit taking imo. Just taking a deeper look at the released results... the samples in the trials are just too small. I know its only preliminary, but I'd like to see the sample sizes much much bigger before 'running around like a headless chook' about this vaccine

(sorry for the joke, but i couldn't resist) hehe

 

[jammin]

IMU has jumped this morning. The trouble is the lack of volume. Looking at the trade history the movement from .265c to .295c was caused by 2 purchases.
The first @10.38am for 39,831 shares moved the SP from .265 to .27c then @ 10.54 buying of 50,000 shares drove the price from .27 to .295 With the low volume, only $24,868 invested, it is difficult to make too many deductions, but the buyers may have wanted much more but cannot find sellers, and are unwilling to buy whist driving the price up further.

 

[bargainbuy]

IMU signs $30 million deal

ASX ANNOUNCEMENT
31 December 2008
Imugene and Merial establish a Strategic Alliance
Merial to develop vaccine candidates from Imugene’s portfolio through to commercial sales
Contract value to Imugene exceeds AUD$30 million over first 7 years
Additional revenue from:
- Further sublicense and registration milestone fees for additional vaccine candidates
- Royalties from sales
Merial and Imugene have signed a comprehensive agreement allowing Merial to obtain exclusive use of the Imugene vector technology. Under the Strategic Alliance, Merial will progress vaccine candidates through the product development process to global sales. Merial will fund all product development and trial costs. Additional vaccine candidates will be evaluated for proof of concept and if successful will also progress into the product development process.
The Strategic Alliance commences December 31st 2008 and Imugene has received an initial payment of US$2m (AUD$2.9m) for reimbursement of past research fees. Further research and licensing payments continue for up to a total of 6 years which allows Merial to assess and commercialise any vaccine candidates developed using the Imugene technology. After this period, Merial will become the exclusive global sublicensee to the FAV & PAV platform technology.
The terms of the Strategic Alliance include the Poultry Productivity Enhancer previously sublicensed to Merial. This vaccine candidate will now be progressed with other FAV vectored vaccine candidates already researched by Imugene and additional vaccine candidates to be disclosed by Merial.
In addition to the above rights, Merial will sub-license any vaccine product that uses either the FAV or PAV vector technology that is to be commercialised. Merial will pay sublicense fees (in addition to the above fees) for each vaccine product, and milestone payments upon first registration for sale of each product. Further income will be generated by royalties on sales.
Royalties are payable on worldwide sales at a base rate of 5 or 6 %. Higher royalty rates are payable on certain products in certain jurisdictions. A mutually agreed minimum royalty income and payment schedule that begins within the Strategic Alliance period has been agreed.
Page 2 of 2
Commenting on the successful conclusion of the exclusive Strategic Alliance negotiations, Dr Warwick Lamb said, “The results from our recent trials and vaccine development activities have been significant and have led to the alliance arrangements with one of the world’s leading animal health companies. Merial and Imugene will now collaborate over the coming years to develop of a suite of vaccines for worldwide sales.”
“We are very pleased to enter this new phase of our relationship with Imugene, said Bob Nordgren, Global Head of Merial Biologicals. This exclusive strategic alliance and licensing agreement gives Merial access to important technology for our innovation of new approaches that could allow our veterinarian customers innovative means for managing important, poorly controlled diseases of swine and poultry. Our relationship dates back to the very beginning of Imugene as a company, and we are confident that Imugene’s adenoviral vectors have significant commercial potential for driving the development of important new products in animal health.”
About Merial
Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs more than 5,400 people and operates in more than 150 countries worldwide. Its 2007 sales were nearly $2.5 billion. Merial Limited is a joint venture between Merck & Co., Inc. and sanofi-aventis. For more information, please see www.merial.com
About Imugene
Imugene Limited (ASX Code: IMU) specialises in the development and commercialisation of novel animal health products for pigs and poultry. Founded in 2002, Imugene has a stable specialist management and scientific team supplemented with extensive use of specialist consultants and contracted trial facilities in the USA and Australia.
Imugene’s range of products under development includes vaccines to prevent important livestock diseases and productivity enhancers to improve the economics of raising commercial livestock. These biologically-based vaccines improve the health and welfare of pigs and poultry and reduce or eliminate the use of antibiotics, chemicals and drugs.
Imugene owns the worldwide rights to the Fowl Adenoviral Vector Delivery System for poultry and the Porcine Adenoviral Vector Delivery System for pigs.
For more information please visit the Imugene website www.imugene.comthirty million deal signed

 

[muzzza]

Re: IMU signs $30 million deal

ASX ANNOUNCEMENT
31 December 2008
Imugene and Merial establish a Strategic Alliance
Merial to develop vaccine candidates from Imugene’s portfolio through to commercial sales
Contract value to Imugene exceeds AUD$30 million over first 7 years
Additional revenue from:
- Further sublicense and registration milestone fees for additional vaccine candidates
- Royalties from sales
Merial and Imugene have signed a comprehensive agreement allowing Merial to obtain exclusive use of the Imugene vector technology. Under the Strategic Alliance, Merial will progress vaccine candidates through the product development process to global sales. Merial will fund all product development and trial costs. Additional vaccine candidates will be evaluated for proof of concept and if successful will also progress into the product development process.
The Strategic Alliance commences December 31st 2008 and Imugene has received an initial payment of US$2m (AUD$2.9m) for reimbursement of past research fees. Further research and licensing payments continue for up to a total of 6 years which allows Merial to assess and commercialise any vaccine candidates developed using the Imugene technology. After this period, Merial will become the exclusive global sublicensee to the FAV & PAV platform technology.
The terms of the Strategic Alliance include the Poultry Productivity Enhancer previously sublicensed to Merial. This vaccine candidate will now be progressed with other FAV vectored vaccine candidates already researched by Imugene and additional vaccine candidates to be disclosed by Merial.
In addition to the above rights, Merial will sub-license any vaccine product that uses either the FAV or PAV vector technology that is to be commercialised. Merial will pay sublicense fees (in addition to the above fees) for each vaccine product, and milestone payments upon first registration for sale of each product. Further income will be generated by royalties on sales.
Royalties are payable on worldwide sales at a base rate of 5 or 6 %. Higher royalty rates are payable on certain products in certain jurisdictions. A mutually agreed minimum royalty income and payment schedule that begins within the Strategic Alliance period has been agreed.
Page 2 of 2
Commenting on the successful conclusion of the exclusive Strategic Alliance negotiations, Dr Warwick Lamb said, “The results from our recent trials and vaccine development activities have been significant and have led to the alliance arrangements with one of the world’s leading animal health companies. Merial and Imugene will now collaborate over the coming years to develop of a suite of vaccines for worldwide sales.”
“We are very pleased to enter this new phase of our relationship with Imugene, said Bob Nordgren, Global Head of Merial Biologicals. This exclusive strategic alliance and licensing agreement gives Merial access to important technology for our innovation of new approaches that could allow our veterinarian customers innovative means for managing important, poorly controlled diseases of swine and poultry. Our relationship dates back to the very beginning of Imugene as a company, and we are confident that Imugene’s adenoviral vectors have significant commercial potential for driving the development of important new products in animal health.”
About Merial
Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs more than 5,400 people and operates in more than 150 countries worldwide. Its 2007 sales were nearly $2.5 billion. Merial Limited is a joint venture between Merck & Co., Inc. and sanofi-aventis. For more information, please see www.merial.com
About Imugene
Imugene Limited (ASX Code: IMU) specialises in the development and commercialisation of novel animal health products for pigs and poultry. Founded in 2002, Imugene has a stable specialist management and scientific team supplemented with extensive use of specialist consultants and contracted trial facilities in the USA and Australia.
Imugene’s range of products under development includes vaccines to prevent important livestock diseases and productivity enhancers to improve the economics of raising commercial livestock. These biologically-based vaccines improve the health and welfare of pigs and poultry and reduce or eliminate the use of antibiotics, chemicals and drugs.
Imugene owns the worldwide rights to the Fowl Adenoviral Vector Delivery System for poultry and the Porcine Adenoviral Vector Delivery System for pigs.
For more information please visit the Imugene website www.imugene.comthirty million deal signed

Has gone up 100% today with the news of this.. Do you know much about the company yourself? Holder? Watching...

 

[mark_au]

Been hanging on to this one for some time now... it would be really great to see them finally get some products out to market...

 

[pixel]

Amazingly, this dog isn't dead yet. In fact, it seems to have been reborn via a 1c capital raising from sophisti-cats. Will they simply pump for a 50% quickie? Or is there more upside to come?



I'm having a small bet to the upside.

 

[pixel]

Amazingly, this dog isn't dead yet. In fact, it seems to have been reborn via a 1c capital raising from sophisti-cats. Will they simply pump for a 50% quickie? Or is there more upside to come?

I'm having a small bet to the upside.

Winning collected. Mustn't be greedy in cases like this. If I didn't get set near the bottom, I find it best to take quickies.

 

[greggles]

Amazingly, this dog isn't dead yet. In fact, it seems to have been reborn via a 1c capital raising from sophisti-cats. Will they simply pump for a 50% quickie? Or is there more upside to come?

Hey Pixel, IMU is still not dead more than four years later. In fact, it's been going for another little run over the last couple of weeks on the back of some encouraging news about a vaccine they are developing. It shot out of the gate nicely this morning.

You still keeping an eye on this one?

 

[Joules MM1]

296 buyers for 103,017,886 units bid x 61 sellers for 24,250,192 units offer
todays commsec front page depth

price is impulsive, both 21 day & 13 week money flows (Twiggs) + accum/distributions are in clear ascention mode

 

[Joules MM1]

https://twitter.com/i/moments/986210634487476224

immunotherapy getting more and more focus groups and studies ...

 

[Assasin]

Anyone following IMU here? Extremely promising next six months. Has been a brilliant short term trader plus doubled its SP in recent times.

 

[HelloU]

up 9% on vol 36M......cannot say anymore about results and stuff - just giving facts - as 7seven member bloke posted today that I "need more real life experience before giving advice". So...DYOR (not advice 7seven bloke)

 

[Assasin]

up 9% on vol 36M......cannot say anymore about results and stuff - just giving facts - as 7seven member bloke posted today that I "need more real life experience before giving advice". So...DYOR (not advice 7seven bloke)

Ha, sounds like your being haunted.

Yes, up 9% and even a bit more now. Got to break through 4c to see blue sky but setting up nicely to have a crack at it. Certainly dancing up the bollies line and a strong ascending wedge.
Looking good and with announcements right around the corner.